Firms that meet quality standards will not be able to routinely produce drugs that are “essentially a copy of a marketed drug,” language important to drug manufacturers, writes Jill Wechsler for Pharmaceutical Technology.

Kapitall points to three biotech and drug manufacturers with FDA-approved drugs that stand to benefit from the new legislation: Forest Laboratories (NYSE: FRX), which develops, manufactures, and sells branded and generic ethical drug products; Allergen (NYSE: AGN), which operates as a speciality healthcare company; and Bristol-Myers Squibb (NYSE: BMY), which develops and delivers medicines that help fight serious diseases.

Looking at XPH’s holdings, FRX is 3.8%, AGN is 3.5% and BMY is 4.0%.

Other pharmaceutical ETFs include:

  • PowerShares Dynamic Pharmaceuticals Portfolio (NYSEArca: PJP): up 48.3% year-to-date; FRX is 3.2%; AGN is 2.8%; BMY is 5.8%
  • iShares U.S. Pharmaceuticals ETF (NYSEArca: IHE): up 37.0% year-to-date; FRX is 2.9%; AGN is 4.2%; BMY is 7.1%
  • Market Vectors Pharmaceutical ETF (NYSEArca: PPH): up 31.8% year-to-date; FRX is 2.3%; AGN is 4.4%; BMY is 5.5%
  • RBS Global Big Pharma ETN (NYSEArca: DRGS): up 27.4% year-to-date; FRX is 3.2%

For more information on the pharma sector, visit our pharmaceuticals category.

Max Chen contributed to this article.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.